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Abstract
Background: Infectious cDNA clones are a prerequisite for directed genetic manipulation of RNA viruses. Here, a
strategy to facilitate manipulation and rescue of classical swine fever viruses (CSFVs) from full-length cDNAs present
within bacterial artificial chromosomes (BACs) is described. This strategy allows manipulation of viral cDNA by
targeted recombination-mediated mutagenesis within bacteria.
Results: A new CSFV-BAC (pBeloR26) derived from the Riems vaccine strain has been constructed and subsequently
modified in the E2 coding sequence, using the targeted recombination strategy to enable rescue of chimeric
pestiviruses (vR26_E2gif and vR26_TAV) with potential as new marker vaccine candidates. Sequencing of the BACs
revealed a high genetic stability during passages within bacteria. The complete genome sequences of rescued
viruses, after extensive passages in mammalian cells showed that modifications in the E2 protein coding sequence
were stably maintained. A single amino acid substitution (D3431G) in the RNA dependent RNA polymerase was
observed in the rescued viruses vR26_E2gif and vR26, which was reversion to the parental Riems sequence.
Conclusions: These results show that targeted recombination-mediated mutagenesis provides a powerful tool for
expediting the construction of novel RNA genomes and should be applicable to the manipulation of other RNA viruses.
Keywords: RNA, Genome, Targeted recombination, Bacterial artificial chromosome, Genetic stability, RNA virus, Pestivirus,
Classical swine fever virus
Background
Bacterial artificial chromosomes (BACs) are ideally suited
for the stable maintenance of large DNA sequences de-
rived from viral genomes [1]. A considerable number of
BAC systems have been established for large DNA viruses;
in particular many different herpesvirus genomes have
been cloned into BACs (for review see [2]). The first BAC
systems using RNA virus cDNAs were described for coro-
naviruses [3-6] and recently the first BAC containing a
full-length cDNA for a negative-stranded RNA virus was
described [7]. Similarly, cDNAs corresponding to the full-
length genomes of members of the Flaviviridae family
(Japanese encephalitis virus [8] and Dengue virus [9]) have
been inserted into BACs.
BACs containing full-length cDNAs of pestiviruses (also
within the Flaviviridae), including bovine viral diarrhea
virus (BVDV) and classical swine fever virus (CSFV) have
recently been established [10,11]. Infectious pestiviruses
can be rescued using RNA transcripts derived from these
BACs. The pestiviruses have single stranded positive sense
RNA genomes, about 12.3 kb in length, which includes a
single long open reading frame, encoding a large polypro-
tein, flanked by 5′ and 3′ untranslated regions (UTRs) that
are critical for autonomous replication of the genome
[12,13]. The polyprotein is cleaved by cellular and viral pro-
teases into four structural proteins (nucleocapsid protein C,
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envelope glycoproteins Erns, E1 and E2) and eight non-
structural proteins (Npro, p7, NS2, NS3, NS4A, NS4B,
NS5A and NS5B). The availability of genetically defined
and stable pestivirus BACs facilitates the functional study of
viral proteins or RNA structures and also the development
of new marker vaccine candidates. Several CSFV vaccines
with marker properties based on chimeric pestiviruses have
been developed over the years [14]. In particular, chimeric
pestiviruses with substitution of the entire E2 protein have
been described [15-17] but also mutants with more subtle
modifications, such as the modification of the important
TAV-epitope [18] within the CSFV-E2 protein [19,20] are
promising marker vaccine candidates.
Manipulation of BACs using traditional cloning proce-
dures can be difficult (e.g. because of a lack of convenient
restriction enzyme sites) and thus a range of methodologies
that apply bacterial genetics, including homologous recom-
bination (e.g. Red/ET homologous recombineering) within
the E. coli host, have been developed (for review, see [21]).
The use of homologous recombination allows site-directed
mutagenesis of BACs [22] and, by employing a counter-
selection scheme, specific modifications can be obtained
without leaving residual “foreign” sequences [23]. The
main advantage of this method is that there are no target
limitations (e.g. based on size or location) and no need for
suitable restriction sites. The integration of the modified
sequence is performed in vivo (within E. coli) thereby po-
tentially being more accurate than in vitro approaches like
PCR-based methods. Although in vitro cloning approaches
based on the use of high-fidelity polymerases for PCR
amplification have significantly improved in recent years,
the use of in vivo approaches should allow a more accurate
method of mutagenesis due to the use of the cells own
high-fidelity replication system which includes proof read-
ing. Whereas BAC recombination has been commonly
used for modifying DNA viruses, there are only very few
reports about the use of this technology for RNA viruses
[7,24,25].
Here, a generally applicable strategy for the manipula-
tion and rescue of chimeric pestiviruses from BACs is
described as a model, and the flexibility of this approach
is demonstrated by generating different modifications in
the viral cDNA of the new CSFV-BAC, pBeloR26, de-
rived from the modified live vaccine strain “C-strain
Riems”. The targeted recombination-mediated mutagenesis
described here includes the substitution of the 9 amino acid
(aa) linear TAV-epitope (TAVSPTTLR) present in the E2
protein with the corresponding region (TTVSTSTLA) of a
heterologous pestivirus (border disease virus, BDV, strain
“Gifhorn”) and also the replacement of the entire CSFV E2
protein coding region with the whole E2 coding region
from the same BDV, to generate marked vaccine viruses
that can be discriminated using specific anti-E2 mono-
clonal antibodies. The genetic stabilities of both the BAC
constructs (within E. coli) and the rescued viruses have also
been assessed.
Methods
Cells and viruses
Porcine kidney (PK15) and sheep fetal thymoid (SFT-R)
cells were grown at 37°C (with 5% (v/v) CO2) in Dulbecco’s
minimal essential medium (DMEM) supplemented with 5%
(v/v) pestivirus-free fetal calf serum. Virus from a bait con-
taining the modified live vaccine CSFV “C-strain Riems”
(Riemser Arzneimittel AG, Germany) was propagated once
in PK15 cells and termed vRiemser. RNA obtained from
BDV strain “Gifhorn” [26] was used for amplification of the
Gifhorn E2-coding sequence.
DNA oligonucleotides
Oligonucleotide primers used are listed in Additional file 1:
Table S1.
BAC constructs
The BAC construct, pBeloR26, was constructed using the
long RT-PCR method as previously described [11] using
RNA derived from the “C-strain Riems”. Briefly, full-length
viral cDNAs flanked by NotI sites were amplified by long
RT-PCR using primers 5′Cstrain_T7_Not1 (which includes
a T7 promotor for in vitro transcription, a NotI site and a
region corresponding to the first 44 nt of the genome) and
3′CSFV_Not1 (that contains a NotI site and sequence
complementary to the 3′-terminal 35 nt of the genome
that are conserved among many CSFVs including the C-
strain). The product (ca. 12.3 kbp) was digested with NotI
and inserted into similarly digested pBeloBAC11 (New
England Biolabs, GenBank accession U51113). All BACs
were modified and maintained in E. coli DH10B cells (Invi-
trogen) grown at 37°C in LB medium containing chloram-
phenicol (Cam, 15 μg/ml). The electroporation of bacteria
was performed in 0.1 cm cuvettes using 1 pulse at 1800 V,
25 μF and 200 Ω in a Gene Pulser Xcell (Bio-Rad). BACs
to be used as templates for long PCR or for screening by
restriction enzyme digestion were purified from 4 ml over-
night cultures of E. coli DH10B using the ZR BAC DNA
Miniprep Kit (Zymo Research). BACs required for direct
genome sequencing were purified from 500 ml cultures
using the Large-construct kit (Qiagen).
Modification of the CSFV cDNA by Red/ET recombination
Modifications to the full-length CSFV cDNA were accom-
plished in E. coli DH10B (streptomycin resistant, StrepR)
using the Counter Selection BAC Modification Kit (Gene
Bridges, Heidelberg, Germany).
The Red/ET recombination involved three steps (i-iii).
Step i) the temperature-sensitive pRedET expression plas-
mid (Gene Bridges) was introduced into electroporation-
competent E.coli DH10B cells containing the parental
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BAC (phenotype CamR, StrepR). The pRedET expresses
the phage lambda proteins redα, redβ and redγ, under
control of the arabinose-inducible pBAD promoter, al-
lowing homologous recombination to occur. Immediately
after electroporation, pre-warmed LB medium without an-
tibiotics (1 ml) was added to the cells which were then in-
cubated at 30°C for 1 hour, prior to spreading onto agar
plates containing Cam (15 μg/ml) and tetracycline (Tet)
(3 μg/ml) and then incubated at 30°C overnight to main-
tain the pRedET. The presence of the pRedET plasmid
(conferring TetR) was verified by visual inspection of BAC-
DNA preparations from the CamR/TetR colonies using
agarose gel electrophoresis. Step ii) counter-selection mar-
ker cassettes with an extra NotI site for screening purposes
(rpsL-neo, 1325 bp) were amplified by PCR using primers
with 30 nt or 50 nt extensions that were homologous to the
target site in the BAC using the rpsL-neo plasmid (Gene
Bridges) as template and the Phusion hot start II HF DNA
polymerase (Thermo Scientific) with cycling conditions as
follows: 98°C for 30s, followed by 35 cycles of 98°C for 10s,
60°C for 20s, 72°C for 60s, and 1 cycle at 72°C for 4 min.
The PCR products (ca. 1400 bp) were isolated on 1% (w/v)
TBE agarose gels and purified using a GeneJET gel extrac-
tion kit (Thermo Scientific). Samples (30 μl), from an E. coli
culture containing pRedET and the parental BAC grown
overnight at 30°C in LB media (Cam, Tet), were used to in-
oculate 1.4 ml of fresh LB media with the same antibiotics
to obtain exponentially growing bacteria at 30°C. Red/ET
recombination proteins were induced by adding 50 μl of
10% (w/v) L-arabinose (Sigma). The PCR product (200 ng)
containing the rpsL-neo cassette was introduced into these
bacteria using electroporation (as above). Following elec-
troporation, the cells were grown at 37°C for 70 min (to
allow recombination) and then selected on plates contain-
ing Cam (15 μg/ml), Tet (3 μg/ml) and kanamycin (Kan,
15 μg/ml) overnight at 30°C to maintain the pRedET. Note,
the rpsL cassette confers Streptomycin sensitivity (StrepS)
onto the resistant DH10B strain and the neo confers Kana-
mycin resistance (KanR). The correct phenotype (CamR,
KanR, TetR, StrepS) of the resulting colonies was con-
firmed by streaking the colonies onto plates containing
Cam (15 μg/ml), Tet (3 μg/ml) and Kan (15 μg/ml) and
grown at 30°C. Importantly, for the third step, the replace-
ment of the rpsL-neo cassette (using counter-selection),
the selected colonies were also streaked onto plates con-
taining Cam (15 μg/ml) plus Strep (50 μg/ml) and shown
to be StrepS indicating incorporation of a functional rpsL
gene. The structures of the intermediate BACs were veri-
fied by restriction enzyme analysis and sequencing around
the inserts. Step iii) the replacement of the rpsL-neo selec-
tion cassettes from the intermediate constructs using linear
DNA fragments was achieved through counter-selection
and Red/ET recombination. Again, the homologous se-
quences at the ends of the DNA fragment were used for
Red/ET mediated recombination events to replace the
rpsL-neo cassette with the sequence of interest. Counter-
selection against the rpsL-neo cassette (phenotype CamR,
KanR, TetR, StrepS) was employed using media containing
Cam (15 μg/ml) and Strep (50 μg/ml) to isolate the re-
quired derivatives (phenotype CamR and StrepR).
Initially, the intermediate construct, pBeloR26_E2rpsLneo
(Figure 1), was generated using Red/ET recombination by
insertion of the rpsL-neo cassette with an extra NotI site
for screening purposes which was amplified using pri-
mers Criems-TAVfor and Criems-TAVrev (Additional file 1:
Table S1) in place of the TAVSPTTLR coding sequence
(27 nt). Secondly, the rpsL-neo cassette in this intermediate
construct was then replaced using counter-selection Red/
ET recombination using a single-stranded oligonucleotide,
Riems_TAV_Gifhorn (Additional file 1: Table S1) with the
same homology arms as used for the rpsL-neo cassette, to
introduce the coding sequence for the BDV “Gifhorn” epi-
tope sequence (TTVSTSTLA). The resulting construct was
named pBeloR26_TAV (Figure 1). The initial intermediate
construct (with rpsL-neo) was then used to produce the
pBeloR26_E2gif construct (Figure 1). For this, the E2 coding
sequence was amplified from cDNA prepared from BDV
“Gifhorn” RNA using two different primer pairs, one set
with 50 nt homology arms (Criems_E2_gifFlong/Criems_
E2_gifRlong) and another with 30 nt homologous se-
quences (Criems_E2_gifF/Criems_E2_gifR).
For generation of BACs with substitution of the entire
E2 coding sequences, PCR products consisting of the se-
quence of interest flanked with homology arms identical
to the target area were generated by PCR (as for the rpsL-
neo cassette). For making constructs with substitution of
shorter sequences (e.g. the TAV-epitope), the recombin-
ation was achieved using synthetic single stranded oligonu-
cleotides rather than PCR products. Pre-heating of single
stranded oligonucleotides at 95°C for 2 min followed by
snap-freezing, prior to electroporation, empirically showed
the best results. In each case, the DNA molecules were in-
troduced into E. coli containing the BAC derivatives in-
cluding the rpsL-neo cassettes together with the pRedET
plasmid by electroporation as described above. The struc-
tures of the modified BACs were verified by restriction
enzyme analysis and subsequent full-genome sequencing
(see below).
Rescue of viruses and virus growth curves
BAC DNA (1 μg) was linearized with NotI or 1 μl BAC
DNA was used as template for long PCR amplification
using primers 5′C-strain_T7_Not1 and 3′CSFV (Additional
file 1: Table S1). Linearized BACs or PCR products were
purified with the GeneJet PCR purification kit (Thermo
Scientific) and transcribed in vitro using a Megascript T7
kit (Invitrogen). Viruses were rescued from RNA transcripts
(1 to 5 μg) by electroporation of porcine (PK15) or ovine
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(SFT-R) cells essentially as described previously [24]. Cells
were analysed using immunofluorescence microscopy (typ-
ically after 3 days) for the expression of NS3 and E2 pro-
teins using specific monoclonal antibodies (mAbs), these
were anti-NS3 (WB103/105, pan-pestivirus), anti-CSFV E2
(WH211, WH303, both CSFV specific) and anti-BDV E2
(WB166, BVDV/BDV specific) (AHVLA Scientific, United
Kingdom) together with Alexa 488 conjugated goat anti-
mouse IgG antibody (Molecular Probes, Invitrogen). The
nuclei of cells were visualized using DAPI (Vector Labora-
tories) and images were recorded using a BX63 fluores-
cence microscope (Olympus). For peroxidase staining, cells
were fixed and stained for the presence of pestivirus anti-
gens using biotinylated pig anti-CSFV/BVDV polyclonal
IgG followed by avidin-conjugated horseradish peroxidase
(eBioscience) as previously described [27]. The same stain-
ing procedure was also performed using the anti-E2 mAbs.
Samples containing virus-positive cells were passaged onto
new cells. Virus growth curves were generated as previously
described [24]. Briefly, PK15 or SFT-R cells were infected at
a multiplicity of infection (MOI) of 0.1 pfu/cell and grown
for three days. At 2, 8, 24, 48 and 72 hours post infection
(PK15) or at 3, 12, 24, 48 and 72 hours post infection
(SFT-R), cell samples were harvested for virus titration.
Cell samples containing virus from each time point were
assayed on PK15 or SFT-R cells by limiting dilutions and
grown for three days to determine the virus titre (as
TCID50/ml).
Genome sequencing
BAC DNAs (5 μg), purified using the Large-construct
kit (Qiagen), or PCR products (1 μg) amplified from viral
cDNA or from BACs using the long PCR method (as
above) were consensus sequenced using a 454 FLX (Roche)
or an Ion PGM (Life Technologies). Both Newbler (Roche)
and the bwa.bwasw alignment algorithm [28] were used for
mapping the reads to the expected sequence. A combin-
ation of Samtools [29] and LoFreq SNV-caller [30] was
used for downstream single nucleotide variant (SNV) ana-
lysis. Finally, clone consensus sequences were aligned using
MAFFT in the Geneious software platform (Biomatters).
Results
Generation of a BAC containing full-length cDNA
corresponding to the modified live vaccine “C-strain Riems”
BACs containing the full-length cDNA corresponding
to the parental vRiemser (“C-strain Riems”) were con-
structed according to the method described previously
for the “Paderborn” strain of CSFV [11]. BACs containing
the complete CSFV cDNAs were identified by restriction
NS2C Erns E1NPro E2 p7 NS3 4A NS4B NS5A NS5B
R26
12316 nt
E2gif
R26_E2gif
12316 nt
R26_TAV
12316 nt
nt 1  374  878 1175 1856 2441   3560  3770       5141       7190  7382    8423      9914      12069 12316
R26_rpsLneo
13614 nt
aa 1    169  273  501   1137      1590          2273  2337   2684    3180            3898
NS2C Erns E1NPro E2 p7 NS3 4A NS4B NS5A NS5B
NS2C Erns E1NPro E2 p7 NS3 4A NS4B NS5A NS5B
NS2C Erns E1NPro p7 NS3 4A NS4B NS5A NS5B
rpsL-neo
(1325 nt)
E2
693-828
E2
838-1066
NotI
TTVSTSTLA
829-837
E2
693-828
E2
838-1066
TTVSTSTLA
829-837
E2gif
693-828
E2gif
838-1066
TAVSPTTLR
829-837
E2
693-828
E2
838-1066
Figure 1 Schematic representation of the CSFV genome organization and the BACs constructed and used in this study. Nucleotide (nt)
and amino acid (aa) positions within R26 for the 5′ and 3′ termini together with the translational start and stop codons of the polyprotein coding
region plus cleavage sites used to make the individual proteins (Npro, C, Erns, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) are indicated.
Insertion of the rpsL-neo in place of the TAV-epitope within CSFV E2 for the intermediate construct (R26_rpsLneo) and the subsequent replacement
with the TTVSTSTLA sequence (R26_TAV) and the complete substitution of the E2 sequence (R26_E2gif) are shown. Names of BAC constructs begin
with “pBelo” and rescued viruses with “v” (e.g. pBeloR26 and vR26). Cell culture passage no. of virus is indicated with “/P” (e.g. vR26/P-4).
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digest analysis and following linearization by NotI, RNA
transcripts were produced and electroporated into PK15
cells. This screening resulted in the identification of a
BAC containing a cDNA insert of 12316 nt, pBeloR26
(Figure 1), which yielded infectious virus, termed vR26,
that could be propagated in SFT-R cells (Figure 2, upper
panels) and in PK15 cells (Figure 3). The rescued vR26
displayed higher growth rate at the early stage (about 10-
fold difference in virus yield at 24 h) compared to the par-
ental vaccine virus, but after 48 hours similar virus titres
were obtained (Figure 3). Full-genome sequencing of the
cloned BAC template, pBeloR26, revealed a number of dif-
ferences throughout the genome when compared to the
full-length consensus sequence of the cDNA used for the
cloning procedure (see Table 1). These differences are
non-representative variants within the cDNA. Overall, the
BAC sequence differed from the cDNA sequence in 18
positions, 9 of these lead to predicted amino acid substitu-
tions within the polyprotein; one in each of Npro, Erns, E1,
E2 and NS3 and four amino acid substitutions in NS5B
(Table 1). When compared to the published reference se-
quence (GenBank accession AY259122.1), the pBeloR26
BAC sequence differed at an additional 11 positions, 1 of
these lead to a predicted amino acid substitution and there
was one large insertion (27 nt) in the hypervariable region
of the 3′-UTR (Additional file 2: Table S2).
Homologous recombination to obtain CSFV E2
chimeric constructs
To determine the utility of the targeted recombination-
mediated mutagenesis system for pestiviruses, two differ-
ent modifications of the E2 protein coding sequence
within pBeloR26 were generated using the Red/ET re-
combination methodology. Initially, the sequence en-
coding the linear TAV-epitope (TAVSPTTLR) within the
CSFV-E2 was substituted with the sequence encoding
the corresponding region (encoding TTVSTSTLA) from
the BDV strain “Gifhorn” as described in the Materials
and Methods section. More than 90% of the colonies ob-
tained using this procedure contained the required BAC
Anti-NS3   
(WB103/105)
Anti-CSFV E2
(WH303)
vR
26
vR
26
_E
2g
if
vR
26
_T
AV
vG
ifh
or
n
Anti-BDV E2
(WB166)
Anti-CSFV E2
(WH211)
Figure 2 Antibody reaction patterns of pestivirus infected cells. SFT-R cells were infected with vR26 and its two derivatives vR26_E2gif and vR26_TAV
plus vGifhorn [26]. After 72 h, the cells were fixed and stained with monoclonal antibodies against the NS3 protein (WB103/105, left column), the CSFV E2
protein (WH303 and WH211, middle columns) and the BDV E2 protein (WB166, right column) as indicated and viewed using a fluorescence microscope.
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structure as determined by NotI digestions. The complete
genome sequences of the CSFV cDNA within two selected
BACs, designated pBeloR26_TAV have been verified (data
not shown). In addition, the complete coding sequence
(1119 nt) for the CSFV-E2 protein was substituted by the
corresponding sequence from BDV “Gifhorn”. Again more
than 90% of the colonies obtained contained the required
BAC and the same proportion of correctly recombined
BACs was obtained using either 30 nt or 50 nt homology
arms. The chimeric BAC was designated, pBeloR26_E2gif
and the complete virus genome sequence (cDNA) was
verified (data not shown).
Rescue of modified virus from recombined BACs
After electroporation with RNA transcripts derived from
either pBeloR26_TAV or pBeloR26_E2gif a large number
of CSFV NS3-positive cells could be observed (data not
shown) and chimeric virus stocks, termed vR26_TAV and
vR26_E2gif, were generated after further passages in cells.
Cells infected with these viruses and with the parental
vR26 and vGifhorn strains were all stained with mAbs di-
rected against the NS3 protein (Figure 2). However, in
contrast to the parental vR26 virus, the chimeric viruses
rescued from the recombined BACs were not recog-
nized by anti-E2 mAbs specific for the CSFV-E2 proteins
(Figure 2) and thus, consistent with their structure, dis-
played the same antibody reaction pattern as vGifhorn.
Two different anti-CSFV E2 mAbs, WH211 and WH303,
were used for the staining and the latter has been shown
previously to target the TAV-epitope [18]. As anticipated,
cells infected with either the vGifhorn or with the chimeric
vR26_E2gif could be shown to express the “Gifhorn” E2
protein using staining with an anti-BDV mAb (Figure 2).
The presence of the BDV epitope TTVSTSTLA in vR26_
TAV was insufficient to permit efficient recognition by this
anti-BDV mab, although a weak signal was observed in
some cells.
Genetic stability of the BACs in the bacterial host
The BAC constructs pBeloR26 and pBeloR26_E2gif were
analysed for the genetic stability of the cDNA to deter-
mine the suitability of the BAC vector for maintaining
full-length pestivirus cDNAs. E. coli DH10B cells con-
taining the BACs were passaged 15 times, by overnight
growth, and the complete viral cDNAs within the BACs
were sequenced after the 1st and the 15th passage. No
mutations were observed within the 12316 nt virus cDNA
sequences after this extensive propagation of the BACs in
the bacterial host, indicating a highly stable system for the
maintenance of complete pestivirus cDNA sequences.
Genetic stability of viruses rescued from the BACs
The viruses, vR26 and vR26_E2gif, rescued from their re-
spective BAC constructs, were also tested for their genetic
stability within mammalian cells. Linearized BAC DNA
was transcribed in vitro and the RNA was electroporated
into PK15 cells. Three days after electroporation the cells
were stained with the anti-NS3 antibody to detect the
presence of replicating virus. Samples containing virus
positive cells were passaged onto new cells, this process
Hours
TC
ID
5
0/m
l
0 12 24 36 48 60 72
10 2
10 3
10 4
10 5
10 6
vR26
vRiemser
Figure 3 Growth characteristics of vR26 compared to the
parental vRiemser. The growth of the rescued vR26 and the parental
vRiemser strains was evaluated in PK15 cells using an MOI of 0.1 pfu/
cell. Virus titers were determined from harvests prepared at 2, 8, 24, 48,
and 72 h post infection. Data are represented as mean + SD (n = 3).
Table 1 Nucleotide and amino acid differences between
the consensus cDNA sequences of the parental vaccine
virus (vRiemser), the cloned BAC cDNA (pBeloR26) and
cDNA of the rescued vR26/P-12
Region nt
position
vRiemser
(cDNA)
pBeloR26
(BAC cDNA)
vR26/P-12
(cDNA)
aa change
(in pBeloR26)
Npro 695 G A A E108K
Erns 1427 C T T H352Y
E1 2364 T C C I664T
E2 3068 G A A D899N
NS2 4441 A G G -
NS3 5500 A G G -
5530 A G G -
6043 T C C -
6201 T C C V1943A
NS5A 9589 T C C -
NS5B 10079 A G G M3236V
10134 A G G K3254R
10272 A G G K3300R
10665 G A G* G3431D
3′ UTR 12128 T A A
12136 T C C
12137 C T T
12152 T A A
*Nt position 10665 in vR26/P-12 is reverted from A to G as in the parental cDNA.
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was repeated for 12 separate passages (each of three days).
The virus titre (as TCID50/ml) was determined for each
passage. Passage of the rescued vR26_E2gif chimeric virus
in PK15 cells resulted in rapidly decreasing virus titres
and was discontinued after the 2nd passage (Figure 4A).
Instead, further passage of this chimeric virus was per-
formed in ovine SFT-R cells (the preferred cell type for
BDV) and resulted in much higher titers of the chimeric
virus. Virus titers reached more than 106 TCID50/ml
after the 1st passage and remained stable for 12 pas-
sages (Figure 4A). The rescued vR26 was also efficiently
propagated on the SFT-R cells but maintained a slightly
lower titer than the vR26_E2gif chimeric virus (Figure 4A).
To check that the viruses retained their antibody reaction
properties (Figure 2) after these passages, cells were in-
fected with viruses from the 12th SFT-R cell culture pas-
sage (termed vR26/P-12 and vR26_E2gif/P-12) and stained
with a polyclonal anti-pestivirus serum and with specific
mAbs directed against the CSFV-E2 and BDV-E2 proteins
(Figure 4B). Cells infected with either the vR26/P-12 or
the chimeric vR26_E2gif/P-12 were each detected by the
polyclonal anti-pestivirus serum as expected. The anti-
CSFV-E2 mAb specifically detected cells infected with
vR26/P-12 but not cells infected by the chimeric virus con-
taining the BDV-E2 protein (consistent with the results
shown in Figure 2). In contrast, the anti-BDV-E2 mAb
specifically detected infection by the vR26_E2gif/P-12 and
did not recognize cells infected with vR26/P-12. Each re-
sult is in accord with the structure of the viruses.
The 4th passage of vR26 (vR26/P-4) displayed a slower
growth rate than the virus obtained after 12 passages (see
Figure 5A). It also had a reduced growth rate compared to
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both the vR26_E2gif/P-4 and vR26_E2gif/P-12. The full-
length sequence of pBeloR26 had revealed ten non-silent
mutations compared to the reference sequence (AY25
9122.1) for this virus (Additional file 2: Table S2). Any of
these mutations could be responsible for the impaired
growth acting alone or in concert. For further investiga-
tion of this issue, full length cDNAs prepared from vR26/
P-4, vR26/P-12, vR26_E2gif/P-4 and vR26_E2gif/P-12 were
deep-sequenced using both the 454 FLX and Ion PGM
platforms for comparison and to determine the quasispe-
cies distribution (Additional file 3: Figure S1 and Additional
file 4: Figure S2). Sequencing data from both platforms re-
vealed that both the vR26/P-12 and vR26_E2gif/P-12 were
close to 100% changed at nt position A10665G compared
to the BAC clones (resulting in the predicted amino acid
substitution D3431G within the NS5B protein, the RNA-
dependent RNA polymerase, see Figure 5B). This adapta-
tion is a reversion back to the consensus cDNA sequence
of the parental vaccine virus, vRiemser (Additional file 2:
Table S2). Additionally, vR26/P-4 and vR26_E2gif/P-4 al-
ready showed evidence for this reversion being present
within the population. For vR26/P-4, the level of reversion
was 57%, while for vR26_E2gif/P-4 the extent of change
was 73% (see Figure 5B).
Discussion
In this study, we have established the first BAC containing
the full-length cDNA of a CSFV vaccine strain. The BAC
differed from the parental cDNA sequence in 18 positions
leading to 9 aa substitutions (Table 1). The method that
has been used for the generation of pBeloR26 is based on
full genome amplification of cDNA followed by direct
cloning to obtain the BACs [11]. This approach results in
cDNA clones that reflect the quasispecies composition of
the parental viral RNA and thus it is not guaranteed to ob-
tain cDNA clones corresponding to the consensus se-
quence of the cDNA used. However, it is possible to
correct the mutations using the BAC recombination ap-
proach if a consensus clone is needed. To demonstrate the
utility of the Red/ET mediated recombination method we
have generated a series of modified BACs derived from
this CSFV full-length cDNA. These include BACs with
substitution of the linear TAV-epitope present in the E2
protein and also BACs with substitution of the complete
E2 protein with heterologous pestivirus sequences. We
have also used the same approach for a range of different
targeted modifications within CSFV BACs including spe-
cific deletions and substitutions in the 5′UTR of CSFV
[24] and for insertions of heterologous reporter sequences
into CSFV replicons [25]. Using Red/ET recombination-
mediated mutagenesis for the targeted design, the work can
be expedited and focused, in principal, on any sequence
within the viral genome and is not dependent on the use of
internal restriction sites. The results demonstrate that Red/
ET recombination-mediated mutagenesis of pestivirus BAC
cDNAs provides a useful tool for advancing the construc-
tion of modified pestiviruses.
Cells infected with the parental vR26 virus were recog-
nized by the two anti-E2 mAbs (WH211 and WH303)
specific for the CSFV-E2 proteins, in contrast cells infected
with the modified viruses vR26_TAV and vR26_E2gif, res-
cued from the recombined BACs, were not detected by
these mAbs. Furthermore, as expected, cells infected with
the vR26_E2gif were recognized by the anti-BDV mAb
(WB166) whereas no staining was observed with this anti-
body in vR26 infected cells or in cells with vR26_TAV. The
mAb WH303 recognizes the CSFV TAV-epitope [18] and
the difference in 4 aa between the TAV-epitope and the
corresponding sequence from BDV strain “Gifhorn” is
enough to completely abolish the recognition by this mAb.
The lack of staining of vR26_TAV infected cells by the
WH211 indicated that the TAV-sequence is also impor-
tant for the epitope recognized by this mAb. Thus, the
chimeric pestiviruses, vR26_TAV and vR26_E2gif, contain-
ing heterologous E2 sequences can be readily discrimi-
nated from the vR26 using specific anti-E2 monoclonal
antibodies. These new chimeric pestiviruses represents C-
strain based marked vaccine candidates with the character-
istics desired for safe and efficacious DIVA vaccines against
CSFV. Indeed, vR26_E2gif vaccinated pigs could be effi-
ciently discriminated from C-strain vaccinated pigs and
from CSFV infected pigs using CSFV-E2 specific antibody
ELISAs (Rasmussen et al., unpublished results).
Genetic stability in the bacterial host
Nucleotide sequence data for the pBeloR26 showed a
number of changes from the published reference sequence
for “C-strain Riems”. Some of these differences are present
in the cDNA derived from the vaccine stock at a detect-
able level whereas others may represent low-level variants
within the cDNA or errors introduced by the RT-PCR
amplification. Full-length sequencing revealed that no
changes occurred in the cDNA during extensive propa-
gation in E. coli DH10B of the pBeloR26 and the E2-
chimeric derivative, pBeloR26_E2gif, indicating a very high
stability of these BAC-cloned CSFV cDNAs. This is essen-
tial if this system is to be useful for cloning and sequence
manipulation, and contrasts with stability problems en-
countered with conventional plasmids containing full-
length pestivirus cDNAs [31]. The stability of these BACs
is consistent with previous reports on the stability of BACs
containing other viruses of the family Flaviviridae in
E. coli [8,10].
Genetic stability of rescued viruses
Extensive passaging of the rescued vR26 and the chimeric
virus derivative, vR26_E2gif, resulted in a change at nu-
cleotide position A10665G (resulting in the predicted aa
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change D3431G) within the NS5B coding region. The
same reversion to the consensus sequence for the “C-
strain Riems” virus was observed in two independent virus
populations, derived from independent BACs, and indi-
cates that this substitution is important for efficient growth
of the “C-strain Riems” virus in SFT-R cells. In contrast, all
other nucleotide positions remained unchanged during the
extensive virus propagation including the heterologous E2
sequences (Figure 5B). The glycine (G) residue at position
3431 in the polyprotein is highly conserved amongst CSFV
strains; indeed, alignment of CSFV sequences retrieved
from GenBank did not reveal any variation at that position
(data not shown). Whether this mutation was derived
from the cloning procedure or reflects a low-level variant
present in the parental vaccine stock is unclear.
Conclusions
In summary, the present study shows that targeted recom-
bination-mediated mutagenesis of BACs containing full-
length CSFV cDNA facilitate manipulation and rescue of
chimeric pestiviruses. The system shows high genetic stabil-
ity of the BAC constructs (within E. coli) and the chimeric
viruses rescued from the BACs can be efficiently and stably
propagated in SFT-R cells and this represents a suitable sys-
tem for the production of virus stocks for future marked
vaccine experiments. The strategies employed in this study
have applicability not only for CSFV (and other pestiviruses)
but should be adaptable to the study of other RNA viruses.
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vR26_E2gif/P-4 and vR26_E2gif/P-12 sequence data determined on the
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Additional file 4: Figure S2. Sequence depth per nucleotide position in
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run on the Ion PGM and the 454 FLX sequencing platforms. The horizontally
aligned graphs compare the sequencing depth between the sequencing
platforms for each sample analyzed by BEDTools [32]. The x-axis depicts the
nucleotide position in the viral genome and the y-axis shows the
sequencing depth.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
TBR, IR and MB conceived the study and developed the approach. TBR, PCR, MBF
carried out and optimised the experiments. TBR, UF and DH carried out sequence
analyses. All authors contributed to the interpretation of results. Funding was
obtained by TBR and GJB. All authors contributed to the drafting and revision
of the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We are grateful to Gabriela Adam and Lone Nielsen for excellent technical
assistance. This work was supported by the Danish Research Council for
Technology and Production Sciences [DRCTPS grant 274-07-0198 (to TBR)
and 274-08-0305 (to GJB)].
Author details
1DTU National Veterinary Institute, Technical University of Denmark,
Lindholm, DK-4771, Kalvehave, Denmark. 2Institute of Diagnostic Virology,
Friedrich-Loeffler-Institut, D-17493, Greifswald-Insel, Riems, Germany.
Received: 31 July 2013 Accepted: 14 November 2013
Published: 22 November 2013
References
1. Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH:
Cloning and mutagenesis of a herpesvirus genome as an infectious
bacterial artificial chromosome. Proc Natl Acad Sci USA 1997,
94(26):14759–14763.
2. Tischer BK, Kaufer BB: Viral bacterial artificial chromosomes: generation,
mutagenesis, and removal of mini-F sequences. J Biomed Biotechnol 2012,
2012:472537.
3. Almazan F, Gonzalez JM, Penzes Z, Izeta A, Calvo E, Plana-Duran J,
Enjuanes L: Engineering the largest RNA virus genome as an infectious
bacterial artificial chromosome. Proc Natl Acad Sci USA 2000,
97(10):5516–5521.
4. Balint A, Farsang A, Zadori Z, Hornyak A, Dencso L, Almazan F, Enjuanes L,
Belak S: Molecular characterization of feline infectious peritonitis virus
strain DF-2 and studies of the role of ORF3abc in viral cell tropism. J Virol
2012, 86(11):6258–6267.
5. Almazan F, Dediego ML, Galan C, Escors D, Alvarez E, Ortego J, Sola I,
Zuniga S, Alonso S, Moreno JL, Nogales A, Capiscol C, Enjuanes L:
Construction of a severe acute respiratory syndrome coronavirus
infectious cDNA clone and a replicon to study coronavirus RNA
synthesis. J Virol 2006, 80(21):10900–10906.
6. Almazan F, Galan C, Enjuanes L: Engineering infectious cDNAs of
coronavirus as bacterial artificial chromosomes. Methods Mol Biol 2008,
454:275–291.
7. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE Jr,
Moore ML: A stabilized respiratory syncytial virus reverse genetics system
amenable to recombination-mediated mutagenesis. Virology 2012,
434(1):129–136.
8. Yun SI, Kim SY, Rice CM, Lee YM: Development and application of a
reverse genetics system for Japanese encephalitis virus. J Virol 2003,
77(11):6450–6465.
9. Pierro DJ, Salazar MI, Beaty BJ, Olson KE: Infectious clone
construction of dengue virus type 2, strain Jamaican 1409, and
characterization of a conditional E6 mutation. J Gen Virol 2006,
87(Pt 8):2263–2268.
10. Fan ZC, Bird RC: An improved reverse genetics system for generation of
bovine viral diarrhea virus as a BAC cDNA. J Virol Methods 2008,
149(2):309–315.
11. Rasmussen TB, Reimann I, Uttenthal A, Leifer I, Depner K, Schirrmeier H,
Beer M: Generation of recombinant pestiviruses using a full-genome
amplification strategy. Vet Microbiol 2010, 142(1–2):13–17.
12. Collett MS, Anderson DK, Retzel E: Comparisons of the pestivirus bovine
viral diarrhoea virus with members of the flaviviridae. J Gen Virol 1988,
69(Pt 10):2637–2643.
13. Meyers G, Rumenapf T, Thiel HJ: Molecular cloning and nucleotide sequence
of the genome of hog cholera virus. Virology 1989, 171(2):555–567.
14. Beer M, Reimann I, Hoffmann B, Depner K: Novel marker vaccines against
classical swine fever. Vaccine 2007, 25(30):5665–5670.
15. van Gennip HG, van Rijn PA, Widjojoatmodjo MN, de Smit AJ, Moormann RJ:
Chimeric classical swine fever viruses containing envelope protein E(RNS)
or E2 of bovine viral diarrhoea virus protect pigs against challenge with
CSFV and induce a distinguishable antibody response. Vaccine 2000,
19(4–5):447–459.
16. Reimann I, Depner K, Trapp S, Beer M: An avirulent chimeric Pestivirus
with altered cell tropism protects pigs against lethal infection with
classical swine fever virus. Virology 2004, 322(1):143–157.
Rasmussen et al. BMC Genomics 2013, 14:819 Page 9 of 10
http://www.biomedcentral.com/1471-2164/14/819
17. Rasmussen TB, Uttenthal A, Reimann I, Nielsen J, Depner K, Beer M:
Virulence, immunogenicity and vaccine properties of a novel chimeric
pestivirus. J Gen Virol 2007, 88(Pt 2):481–486.
18. Lin M, Lin F, Mallory M, Clavijo A: Deletions of structural glycoprotein E2
of classical swine fever virus strain alfort/187 resolve a linear epitope of
monoclonal antibody WH303 and the minimal N-terminal domain
essential for binding immunoglobulin G antibodies of a pig
hyperimmune serum. J Virol 2000, 74(24):11619–11625.
19. Reimann I, Depner K, Utke K, Leifer I, Lange E, Beer M: Characterization of a
new chimeric marker vaccine candidate with a mutated antigenic
E2-epitope. Vet Microbiol 2010, 142(1–2):45–50.
20. Holinka LG, Fernandez-Sainz I, O’Donnell V, Prarat MV, Gladue DP, Lu Z,
Risatti GR, Borca MV: Development of a live attenuated antigenic marker
classical swine fever vaccine. Virology 2009, 384(1):106–113.
21. Hall RN, Meers J, Fowler E, Mahony T: Back to BAC: the use of infectious
clone technologies for viral mutagenesis. Viruses 2012, 4(2):211–235.
22. Zhang Y, Buchholz F, Muyrers JP, Stewart AF: A new logic for DNA engineering
using recombination in Escherichia coli. Nat Genet 1998, 20(2):123–128.
23. Muyrers JP, Zhang Y, Testa G, Stewart AF: Rapid modification of bacterial
artificial chromosomes by ET-recombination. Nucleic Acids Res 1999,
27(6):1555–1557.
24. Friis MB, Rasmussen TB, Belsham GJ: Modulation of translation initiation
efficiency in classical swine fever virus. J Virol 2012, 86(16):8681–8692.
25. Risager PC, Fahnoe U, Gullberg M, Rasmussen TB, Belsham GJ: Analysis of
classical swine fever virus RNA replication determinants using replicons.
J Gen Virol 2013, 94(8):1739–1748.
26. Rasmussen TB, Reimann I, Hoffmann B, Depner K, Uttenthal A, Beer M:
Direct recovery of infectious pestivirus from a full-length RT-PCR
amplicon. J Virol Methods 2008, 149(2):330–333.
27. Uttenthal A, Storgaard T, Oleksiewicz MB, de Stricker K: Experimental
infection with the Paderborn isolate of classical swine fever virus in
10-week-old pigs: determination of viral replication kinetics by
quantitative RT-PCR, virus isolation and antigen ELISA. Vet Microbiol 2003,
92(3):197–212.
28. Li H, Durbin R: Fast and accurate long-read alignment with burrows-wheeler
transform. Bioinformatics 2010, 26(5):589–595.
29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
Durbin R: 1000 Genome project data processing subgroup: the sequence
alignment/Map format and SAMtools. Bioinformatics 2009, 25(16):2078–2079.
30. Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, Khor CC, Petric R,
Hibberd ML, Nagarajan N: LoFreq: a sequence-quality aware, ultra-sensitive
variant caller for uncovering cell-population heterogeneity from
high-throughput sequencing datasets. Nucleic Acids Res 2012,
40(22):11189–11201.
31. Ruggli N, Rice CM: Functional cDNA clones of the Flaviviridae: strategies
and applications. Adv Virus Res 1999, 53:183–207.
32. Quinlan AR, Hall IM: BEDTools: a flexible suite of utilities for comparing
genomic features. Bioinformatics 2010, 26(6):841–842.
doi:10.1186/1471-2164-14-819
Cite this article as: Rasmussen et al.: Efficient generation of
recombinant RNA viruses using targeted recombination-mediated
mutagenesis of bacterial artificial chromosomes containing full-
length cDNA. BMC Genomics 2013 14:819.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rasmussen et al. BMC Genomics 2013, 14:819 Page 10 of 10
http://www.biomedcentral.com/1471-2164/14/819
